Quest Diagnostics SVP & CCO Acquires 25 Shares via Dividend Reinvestment

Executive Summary

On October 23, 2026, Quest Diagnostics Inc. ($DGX) filed a Form 4 disclosing an acquisition of common stock by Mark E. Delaney, Senior Vice President and Chief Commercial Officer. On October 21, 2026, Delaney acquired 25 shares of Common Stock at an average price of $235.941 per share, representing a total transaction value of approximately $5,898.53.

Transaction Details

• Security: Common Stock
• Transaction Code: L (Small acquisition eligible for deferred reporting under Rule 16a-6, reported early)
• Shares Acquired: 25
• Price Per Share: $235.941
• Total Investment: $5,898.53
• Ownership Post-Transaction: 10,360 shares held directly
• Context: As noted in the filing footnotes, the acquisition was conducted automatically pursuant to a broker-administered dividend reinvestment plan (DRIP).

Market & Strategic Impact

The transaction carries low trading significance. It represents routine reinvestment of shareholder dividends rather than discretionary open-market buying or selling. While it modestly increases Delaney's direct equity position, it does not provide an actionable directional signal.